BTIG Releases a Buy Rating on Obalon Therapeutics Inc

By Austin Angelo

In a report issued on March 16, Sean Lavin from BTIG reiterated a Buy rating on Obalon Therapeutics Inc (NASDAQ: OBLN), with a price target of $20. The company’s shares closed last Friday at $10.69.

According to TipRanks.com, Lavin is a 5-star analyst with an average return of 10.0% and a 59.6% success rate. Lavin covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Trivascular Technologies, and Boston Scientific Corp.

Obalon Therapeutics Inc has an analyst consensus of Moderate Buy, with a price target consensus of $20.

The company has a one year high of $15.88 and a one year low of $8.27. Currently, Obalon Therapeutics Inc has an average volume of 77.08K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Obalon Therapeutics, Inc. focuses on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. Its product includes medical balloon technology for weight loss therapy which consists of a capsule containing a balloon that is swallowed and then remotely inflated. The company was founded in January 2008 and is headquartered in San Diego, CA.